Latest Articles
-
What Moves Biotech Stocks? Ed Arce Has Answers.
Submitted by The Life Sciences as part of our contributors program . Interview conducted by George S. Mack of The Life Sciences Report (10/18/12) Biotech stocks move on material news, which means clinical data, regulatory progress, new pa...
-
Abbott Q3 Earnings Preview: What We Are Watching
Abbott Labs (NYSE:ABT) is going to announce its Q3 results on October 17. It is the third major healthcare company in our coverage to announce its results after Roche Holdings (PINK:RHHBY) and Johnson & Johnson (NYSE:JNJ) announces its earnin...
-
Abbott Labs Updates: FDA Approves Humira for Colitis
The U.S. Food and Drug Administration (FDA) has finally approved the extension of Abbott Labs ‘ (NYSE:ABT) largest selling drug Humira for the treatment of moderate to severe Ulcerative Colitis (UC). Ulcerative colitis is a chronic inflamm...
-
Abbott’s Ready To Pump Up Vascular Market Share With New Launches
Abbott Labs (NYSE:ABT) has started selling Absorb, the world’s first drug eluting bioresorbable vascular scaffold (DEVS), in international markets including Europe and parts of Asia Pacific and Latin America. Following this launch, we expec...
-
Doctors’ Opposition To Expanded Carotid Stent Use Could Hurt Medical Devices Companies
Medical devices manufacturers including Abbott Labs (NYSE:ABT), Boston Scientific (NYSE:BSX) and Johnson & Johnson (NYSE:JNJ) may have to brace themselves to forgo potential revenues, if the U.S. federal government pays heed to doctors̵...
-
Abbott Labs Stock Can Reach $80 On These Drivers
The last couple of months have been amazing for pharmaceutical companies as their stocks prices have zoomed higher by 20-30%. Abbott Labs (NYSE:ABT) also rose significantly to converge with our $67 price estimate as the company’s earnings ...
-
Abbott Labs: Revised Price Estimate of $67 on Strong Humira Performance
Abbott Labs (NYSE:ABT) recently reported its Q2 results, which were mostly in line with our expectations. To see our full analysis of Abbott’s Q2 earnings, please refer to our note Abbott Meets Expectations as Humira, Nutritionals Drive Gro...
-
Abbott Labs: FDA Panel Backs Humira for Colitis, Gets Additional Treatment Approval In Europe
A U.S. Food and Drug Administration (FDA) advisory panel has backed the use of Abbott Labs ‘ (NYSE:ABT) largest selling drug Humira for the treatment of Ulcerative Colitis (UC) even as the FD A staff has recently raised some concerns about...
-
FDA Raises Concerns About Humira’s Efficacy For Colitis
The U.S. Food and Drug Administration (FDA) has raised efficacy and safety concerns regarding the use of Abbott Labs ‘ (NYSE:ABT) largest selling drug Humira for the treatment of Ulcerative Colitis (UC). According to the FDA, Humira doesn&#...
-
Abbott’s Next-Generation Stent To Enter Europe After CE Approval
Abbott Labs (NYSE:ABT) has won the CE mark status for its next-generation Xience Xpedition, a drug-eluting stent (DES). This means that the product complies with the essential requirements of the relevant European health, safety and environmental...
-
Abbott Plans New Manufacturing Facility To Expand Indian Nutritional Business
Abbott Labs (NYSE:ABT) is taking next steps as part of its plans to strengthen its foothold in the fast-growing India’s nutritional market. The company will be investing approximately $65 million toward building its first nutrition manufact...
-
Pharma Giants Nervous As India Contemplates Regulating Patented Drug Prices
The Indian government is mulling plans to control the prices of life-saving, but highly expensive patented drugs in a bid to make them affordable for the patients. The government is considering taking away patent rights of certain life-saving dru...
-
Abbott Benefits From Humira’s Additional Treatment Approvals In Europe
Humira has been a phenomenal drug for Abbott Labs (NYSE:ABT). While it is already approved for several treatments, or indications, in the U.S. and Europe, it recently added another one to its name in Europe. The drug is now approved for treating ...
-
Abbott Meets Expectations as Humira, Nutritionals Drive Growth
Abbott Labs (NYSE:ABT) reported its Q2 results this Wednesday, which were in line with our expectations. Sales grew by 2% y-o-y to about $9.8 billion on back of growth in its pediatric nutritionals business and key drugs including Humira, AndroGe...
-
Abbott Earnings: Humira And Nutritional Segments In Focus
Abbott Lab s (NYSE:ABT) is going to announce its Q2 results on July 18. It is the second major healthcare company in our coverage to announce its results after Johnson & Johnson (NYSE:JNJ) announces its earnings on July 17. (See our note: ...
